Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents
This application describes the use of the compound (I) or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed.
1. A method of treating a cancer in a subject, comprising (a) administering to the subject a first compound selected from erlotinib and gefitinib until the cancer exhibits resistance to said first compound, then (b) administering to the subject a combination of (i) the first compound selected from erlotinib and gefitinib, and (ii) a second compound which is
or a pharmaceutically acceptable salt thereof, wherein said cancer is selected from non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, and pancreatic cancer.
2. The method of claim 1 , wherein the second compound, or a pharmaceutically acceptable salt thereof is administered to the subject from one to four times daily.
3. The method of claim 2 , wherein the second compound, or a pharmaceutically acceptable salt thereof, is administered to the subject in an amount from about 10 mg/kg to about 55 mg/kg.
4. The method of claim 1 , wherein the cancer is NSCLC.
5. The method of claim 1 , wherein said cancer is breast cancer.
6. The method of claim 1 , wherein said cancer is gastric cancer.
7. The method of claim 1 , wherein said cancer is pancreatic cancer.
8. The method of claim 1 , wherein said cancer is non-small cell lung cancer.